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Germline mutations in the mismatch repair (MMR) genes are associated with Lynch syndrome, also known as hereditary
non-polyposis colorectal cancer (HNPCC) syndrome. Here, we characterise a variant of hMLH1 that confers a loss-of-function MMR
phenotype. The mutation changes the highly conserved Gly67 residue to a glutamate (G67E) and is reminiscent of the
hMLH1-p.Gly67Arg mutation, which is present in several Lynch syndrome cohorts. hMLH1-Gly67Arg has previously been shown to
confer loss-of-function (Shimodaira et al, 1998), and two functional assays suggest that the hMLH1-Gly67Glu protein fails to sustain
normal MMR functions. In the first assay, hMLH1-Gly67Glu abolishes the protein’s ability to interfere with MMR in yeast. In the
second assay, mutation of the analogous residue in yMLH1 (yMLH1-Gly64Glu) causes a loss-of-function mutator phenotype similar to
yMLH1-Gly64Arg. Despite these molecular similarities, an unusual spectrum of tumours is associated with hMLH1-Gly67Glu, which is
not typical of those associated with Lynch syndrome and differs from those found in families carrying the hMLH1-Gly67Arg allele. This
suggests that hMLH1 may have different functions in certain tissues and/or that additional factors may modify the influence of hMLH1
mutations in causing Lynch syndrome.
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Lynch syndrome, also known as hereditary non-polyposis colo-
rectal cancer (HNPCC), is an autosomal dominant cancer
predisposition disorder. Apart from colorectal cancers, affected
individuals are also predisposed to an array or other cancers, such
as endometrial cancer, transitional cell carcinomas of the upper
urothelial tract, carcinoma of the stomach, hepatobiliary and small
intestinal cancers (reviewed in Lynch and de la Chapelle, 2003).
Sets of criteria that trigger investigation of the possibility of a
Lynch syndrome diagnosis include the revised Bethesda and the
Amsterdam I and II criteria, which consider the combinations of
tumours in individuals and families, the age of tumour onset and
pathological features of tumours (Vasen et al, 1999; Umar et al,
2004).
In the 1990s, a number of studies linked Lynch syndrome to
mutations in the mismatch repair (MMR) genes (Fishel et al, 1993;
Bronner et al, 1994; Nicolaides et al, 1994; Papadopoulos et al,
1994; Li, 2003). The MMR proteins prevent the accumulation of
DNA replication errors by detecting and effecting the removal of
base–base mismatches as well as small insertion-deletion loops
from the newly synthesised strand. Tissue samples from tumours
and human cell lines in which MMR has been inactivated show
variation in the length of repetitive DNA sequences (micro-
satellites), a phenomenon known as microsatellite instability
(MSI). These include mononucleotide repeats of adenine, which
are often mutated in MMR-defective cells, and are present in DNA
damage repair genes MRE11, RAD50 and BRCA1, checkpoint
component CHK1 (Yoshikawa et al, 2000; Menoyo et al, 2001;
Giannini et al, 2002; Kim et al, 2007) as well as TGFb-R2, PTEN,
APC and MBD4 (Markowitz et al, 1995; Huang et al, 1996; Kong
et al, 1997; Tashiro et al, 1997; Riccio et al, 1999).
Components of the MMR pathway are highly conserved from
bacteria to human (Modrich, 2006). In eukaryotes, heterodimers of
MSH2-MSH6 (MutSa) and MSH2-MSH3 (MutSb) detect mis-
matches and insertion–deletion loops and form complexes with
heterodimers of MLH1-PMS2 (MutLa), and to a lesser extent with
MLH1-MLH3 (MutLb). hPMS2 contains endonuclease activity that
can initiate the removal of the newly synthesised strand, which
contains the incorrectly inserted base (Kadyrov et al, 2006).
In vitro reconstitution of MMR shows that MutLa is required for
30-directed excision of the mismatch, in addition to factors such as
PCNA, RPA and EXOI (Dzantiev et al, 2004).
More than 450 germline abnormalities of MMR genes have been
described (InSiGHT, http://www.insight-group.org). Whether a
specific missense variant in hMSH2 or hMLH1 confers patho-
genicity can be difficult to determine, as it requires the evaluation
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sof multiple parameters, including statistical analyses of the
segregation of the variant with the phenotype and functional
assessment of the variant protein. Segregation of the variant within
a family may provide some evidence, but this could in theory be
caused by another closely linked mutation. Small family size,
incomplete penetrance of mutations and lack of confirmatory
records on tumours from older generations can often limit the
power of such analyses. Collation of data on variants from
different families is helpful, but is not available if variants are rare
or novel.
There are several functional tests available to assess variant
protein activity, although they each have their limitations. Mismatch
repair-deficient tumour-derived cell lines can be transfected with
plasmid containing variant MLH1 genes and assessed for mutator
phenotype and/or drug-resistance phenotypes (Brieger et al,2 0 0 2 ;
Trojan et al, 2002; Blasi et al, 2006). For C-terminal mutations in
hMLH1 and hPMS2, testing the variant proteins for interactions with
their partner can be informative (Nystrom-Lahti et al, 2002). There
are also in vitro tests for MMR activity, which rely upon the
complementation of MMR-deficient extracts by the variant protein.
However, these assays require expression and purification of
recombinant MMR proteins (Nystrom-Lahti et al, 2002; Heinen
et al, 2002), and although MMR repair in vitro may be deemed
normal when sufficient quantities of the variant protein is used,
some variants are poorly expressed, suggesting that the cellular levels
of the variant may be lower (Kariola et al, 2002). All of these assays
require tissue culture facilities and/or recombinant protein
expression, significant skill, and can be costly. To overcome these
limitations, several yeast and bacteria-based systems for the
functional analysis of variant MMR proteins have been developed.
In both yeast and bacteria, hMLH1 interferes with normal,
endogenous yMMR/bMMR, resulting in enhanced mutation rates
(Shimodaira et al, 1998; Quaresima et al, 2003). Several mutations in
hMLH1 abolish the capacity of the hMLH1-variant to interfere with
yMMR/bMMR, thus restoring normal mutation rates (Shimodaira
et al, 1998; Quaresima et al, 2003; Takahashi et al, 2007). Generally,
in vitro assays concur with findings in such studies (Takahashi et al,
2007). Furthermore, there are alternative/complementary strategies
for assessing hMLH1 function in yeast. The N-terminus of MLH1
contains the highly conserved ATPase domain, allowing analogous
variant hMLH1 mutations to be introduced into yMLH1 (Shcherba-
kova and Kunkel, 1999; Hoffmann et al, 2003). As this method is
restricted to evolutionarily conserved N-terminus residues, hybrid
mammal–yeast MLH1 have been generated to assess MMR function
of hMLH1 variants in budding yeast (Polaczek et al, 1998).
Here, we describe the functional analysis of a variant hMLH1
protein following our description of a Lynch syndrome kindred
with a unique collection of tumours rarely seen in this condition.
Functional analysis of hMLH1 suggests that the mutation of
p.Gly67Glu perturbs the protein’s ability to prevent the accumula-
tion of mutations. This loss-of-function is similar to a previously
analysed allele, hMLH1-Gly67Arg, which has been described in
Lynch syndrome families. Our observations suggest that the loss-
of-function of hMLH1 is not sufficient to predict the type of
tumours. We suggest that other genetic modifiers may be present
to explain the phenotype and/or that the function of hMLH1 may
differ from one cell type to another.
MATERIALS AND METHODS
Plasmids pRS315
Plasmids pRS315 containing hMLH1 and hMLH1-G67R were
kindly provided by Dr Shimodaira. The hMLH1-G67E and
yMLH1-G64R mutations were generated using the Quick
Change Site-directed Mutagenesis kit from Stratagene (La Jolla,
CA, USA) using primers hMLHG67E for 50-AGGGAGGCCTGAA
GTTGATTCAGATCCAAGACAATGGCA CCGAGATCAGG-30 and
hMLHG67Erev for 50-GGGGTTTGCTCAGAGGCTGCAGAAATGCA
TCAAGC-30. Plasmids were introduced into the haploid yeast strain
Y39 (Y55 background, MATa, his4-R1, leu2-R1, ade1-1, lys2HInsE-
A14 CAN1, ura3-N). Plasmid yMLH1-G64E was generated as above
using plasmid yMLH1-G64R as a template and primers yMLHG64E
for 50-CAAATAACAGATAACGGATCTGAAATTAATAAAGCAGA
CCTGCCA-30 and yMLHG64Erev for 50-TGGCAGGTCTGCTTTA
TTAATTTCAGATCCGTTATCTGTTATTTG-30. The yMLH1-G64E
mutation was integrated into the yeast genome by two-step gene
replacement, as described previously (Hoffmann et al, 2003).
Yeast media
Yeast media were generated and used according to (Hoffmann
et al, 2003).
Fluctuation tests
Fluctuation tests were carried out using the method of the median
(Lea and Coulson, 1949; Reenan and Kolodner, 1992). We assessed
11 colonies from three independent transformants for each
mutation.
Immunoblotting
Total protein was extracted from the transformants expressing the
hMLH1variants. A total of 3.5 10
7 cells were disrupted by glass
beads in 200ml 20% trichloroacetic acid (TCA) in a FastPrep
cell disrupter (Thermo Savant, Breda, Netherlands). The glass
beads were removed and the precipitated protein was resuspended
in 100ml sample loading buffer (250mM Tris-HCl, pH 8.0, 5%
glycerol, 0.4% SDS, 1% b-mercaptoethanol, 0.02% Bromophenol
Blue). Equal amounts of protein, as determined by the Bradford
assay, were separated by SDS polyacrylamide gel electro-
phoresis (6%). Proteins were electrophoretically transferred onto a
nitrocellulose membrane (Amersham Biosciences, Amersham, UK),
which was probed first with a mouse hMLH1 antibody (1:500,
G168-15, BD Biosciences, Erembodegem, Belgium), and secondly
with a horseradish peroxidase-conjugated antibody raised against
mouse IgG (1:3000, Dako, Glostrup, Denmark). Expressed protein
was detected by chemiluminescence (Western Lightning Chemilu-
minescence Reagent, PerkinElmer, Waltham, MA, USA).
RESULTS
Genetic analysis and tumour spectrum of the
hMLH1-p. Gly76Glu variant: a case study
A Caucasian male was seen in clinic with a history of male breast
cancer and leiomyosarcoma of the thigh (presenting concurrently
in his third decade), colon cancer (presented in his fourth decade)
and prostate cancer (presented in his fifth decade). There were
colorectal cancers with the age of onset in the fourth decade in his
paternal grandfather and two paternal uncles. This family history
is consistent with the revised Amsterdam criteria for the clinical
diagnosis of Lynch syndrome (Vasen et al, 1999). His father had
oesophageal cancer at the age of 47 years. Other unusual tumours
in carriers of the variant included cervical adenosquamous
carcinoma, oligodendroglioma and prostate cancer.
Initial genetic screening for mutations (by full sequencing) in
the TP53 gene responsible for the Li-Fraumeni syndrome was
negative. The breast cancer susceptibility genes BRCA1 and BRCA2
also did not harbour any mutations as screened by dHPLC
(denaturing high-performance liquid chromatography) and MLPA
(multiplex ligation-dependent probe amplification).
Several of the tumours in this family including the proband’s
sarcoma showed microsatellite instability. Molecular analysis of
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sthe proband’s germline DNA identified a missense variant in the
hMLH1 gene in exon 2 at nucleotide position 200 (c.200 G4A).
This results in an amino-acid substitution from glycine to glutamic
acid (Gly67Glu/G67E). The Gly67Glu mutation segregates with
cancer predisposition across the pedigree.
Expression of hMLH1-G67E does not interfere with yeast
MMR
To determine whether hMLH1-p.Gly67Glu (denoted hMLH1-G67E
henceforth) is functional in MMR, we used two different
approaches.
We took the advantage of the findings that the expression of
functional human MLH1 (hMLH1) interferes with normal MMR in
the budding yeast, whereas several point mutants associated with
Lynch syndrome fail to do so. For example, hMLH1-p.Gly67Arg
(G67R), known to occur in HNPCC families, shows reduced ability
to interfere with yeast MMR in this assay (Figure 1; Shimodaira
et al, 1998). We transformed budding yeast (Y39) with vector only
(pRS315), vector containing hMLH1, hMLH1-G67R or hMLH1-
G67E and assessed the forward mutation rate of CAN1 as well as
the reversion rate of lys2HInsE-A14. CAN1 encodes an arginine
permease that renders cells sensitive to the arginine analogue,
canavanine. Mutations in CAN1 include base substitutions as well
as insertions and deletions, which cause cells to become resistant
to canavanine. The lys2HInsE-A14 contains a homopolymeric run
of 14 adenines, which causes a þ1 frameshift mutation in LYS2
(Tran et al, 1997). Reversion reconstitutes LYS2,a na-amino-
adipate reductase that allows cells to synthesise lysine. Qualitative
assessment of four independent transformants shows that the
‘vector only’ has no discernible effect on mutation rates
of lys2HInsE-A14 (Figure 1A). In contrast, introduction
of ‘vectorþhMLH1’ causes an increase in the mutation rate of
lys2HInsE-A14, consistent with aberrant yMMR. Cells transformed
with the previously characterized mutation, hMLH1-G67R,d on o t
display an increased mutator phenotype, although some of the
transformants do show a stochastic increase (data not shown).
hMLH1-G67E behaved very similarly to hMLH1-G67R in that the
majority of transformants did not show a mutator phenotype
(Figure 1A and data not shown). These observations show that
hMLH1-G67E displays a strongly reduced capacity for interfering
with normal MMR function in budding yeast. We also quantified the
mutation rates using the method of the median (see Materials and
Methods) for both CAN1 and lys2HInsE-A14. Introduction of hMLH1
causes a 18700-fold and 5.1-fold increase in the mutation rate
estimates of lys2HInsE-A14 and CAN1, respectively, whereas hMLH1-
G67R did not enhance the mutation rates (1.2-fold for lys2HInsE-A14
and 0.6-fold for CAN1 change in mutation rates as compared with
‘vector only’; Table 1). hMLH1-G67E shows a similar phenotype to
hMLH1-G67R, with 1.9-fold and 1.1-fold difference compared with
‘vector only’ (Table 1), suggesting that hMLH1-G67E has a similar
loss-of-function phenotype as hMLH1-G67R in this assay.
The hMLH1 and hMLH1-G67R proteins are expressed stably in
yeast cells (Shimodaira et al, 1998). To determine whether this is
also the case for hMLH1-G67E, we carried out western blot
analyses on the four transformants (Figure 1B). Protein extracts
from cells containing hMLH1, hMLH1-G67R and the four
independent transformants of hMLH1-G67E, but not vector only,
showed the diagnostic 80kD band. Thus, hMLH1-G67E is stably
expressed in budding yeast cells, but shows reduced ability to
interfere with normal MMR functions.
yMLH1-G64R confers increased mutation rates
The second yeast assay we employed is based on the observation
that eukaryotic MLH1 homologues are highly conserved in the
N-terminal ATPase domain. Several Lynch syndrome mutations,
including hMLH1-G67R, confer a loss-of-function phenotype for
mutator activity when introduced into the analogous residue in
yeast MLH1 (yMLH1-G64R; Shcherbakova and Kunkel, 1999). We
introduced the G67E change directly into the budding yeast locus
(yMLH1-G64E) and assessed the mutation rates (Table 2). Deletion
of yMLH1 causes a 30-fold and 19000-fold increase in the mutation
rates for CAN1 and lys2HInsE-A14, respectively, compared with
the wild-type strain. The yMLH1-G64R mutant protein confers an
intermediate phenotype, but nevertheless shows highly elevated
mutation rates. The yMLH1-G64E mutation is similar to yMLh1-
G64R, suggesting that changing the G64 residue in yMLH1 to either
a positively charged arginine or a negatively charged glutamate
confers similar inhibition of protein activity during MMR.
DISCUSSION
Characterising MMR gene alterations in Lynch syndrome families
is important in clarifying risk and advising on management issues,
Vector only
Leucine Lysine (lys2::lnsE-A14)
hMLH1
hMLH1-G67R
hMLH1-G67E
1234567
Lane 1: hMLH1
Lane 2: hMLH1-G67R
Lane 4: hMLH1-G67E (transformat 1)
Lane 3: Vector only
Lane 5: hMLH1-G67E (transformat 2)
Lane 6: hMLH1-G67E (transformat 3)
Lane 7: hMLH1-G67E (transformat 4)
B
A
Figure 1 (A) Yeast cells were transformed with vector only (pRS315),
vector containing hMLH1, hMLH1-G67R or hMLH1-G67E and assessed the
forward mutation rate of CAN1 as well as the reversion rate of lys2H
InsE-A14. The hMLH1-G67E mutant shows reduced ability to interfere with
yeast MMR similar to the hMLH1-G67R mutation. (B) Western blot
analyses of the four separate transformants of hMLH1-G67E. Yeast cells
stably express wild-type hMLH1 protein as well as the hMLH1-G67R and
the hMLH1-G67E mutants.
Table 1 Human hMLH1-G67E mutant does not interfere with yeast MMR
Rate
a lys2HInsE-A14±s.e.m. Fold difference Rate CAN1±s.e.m. Fold difference
Vector only 1.2 10
 7 1.1 10
 8 1.0 1.5 10
 6 1.3 10
 7 1.0
hMLH1 2.3 10
 3 1.4 10
 3 18,700 7.7 10
 6 1.2 10
 6 5.1
G67R 1.5 10
 7 4.0 10
 8 1.2 8.6 10
 7 3.4 10
 7 0.6
G67E 2.4 10
 7 1.3 10
 7 1.9 1.7 10
 6 4.9 10
 7 1.1
MMR¼mismatch repair. Mutation rates are assessed in yeast strains expressing the various forms of human MLH1 proteins. Only wild-type hMLH1 was capable of interfering
with the endogenous yeast MMR to increase mutation rates.
aMutation rate estimated as mutation/cell/generation.
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ssuch as cancer surveillance, treatment and prevention. Detailed
study of a family with a tumour spectrum satisfying the
Amsterdam criteria for Lynch syndrome has allowed us to
characterise a variant in hMLH1. Interestingly, in addition to
classic tumours, this family also exhibits a collection of atypical
tumours. Functional analysis of this variant shows that it confers a
loss-of-function mutator phenotype.
The p.Gly67Glu (p.Gly64Glu in yeast) mutation alters an amino-
acid residue in the highly conserved N-terminus of hMLH1
(Ban and Yang, 1998). By analogy to the crystal structure of
bacterial MutL, G67 is positioned on a loop, which is part of the
ATP-binding pocket (Ban and Yang, 1998; Ban et al, 1999). ATP-
binding induces conformational changes in the N-terminus that
allows MutL monomers to dimerise (Ban et al, 1999), thus
facilitating the interaction between hMLH1 and hPMS2. Moreover,
cycles of ATP-binding and hydrolysis have been suggested to
regulate MutLa activity (Tran and Liskay, 2000). Structure
predictions would suggest that the hMLH1-p.Gly67Glu substitution
alters the local conformation of the hMLH1 protein, analogous to
that predicted for hMLH1-pGly67Arg (Ban and Yang, 1998). We
tested this directly by comparing the G67E/G64E mutation to a
previously characterised mutant in the same residue (G67R/G64R)
in two functional assays. It is clear that expressing hMLH1-G67E
does not appear to interfere with yeast MMR, which is not the case
when normal hMLH1 is present. Furthermore, when the analogous
substitution is made in the yeast protein, yMLH1-G64E, this
protein does not sustain MMR fully and is as compromised as
yMLH1-G64R. Thus, we conclude that hMLH1-G67E is a loss-of-
function allele, similar to hMLH1-G67R.
We have identified that hMLH1-G67E segregates with disease in
the family reported and is associated with atypical cancers. This is
in sharp contrast to reported kindreds harbouring the hMLH1-
G67R mutation who only showed classical elements of
Lynch syndrome (Herfarth et al, 1997; Heinimann et al, 1999;
Plevova ´ et al, 2004). Furthermore, the hMLH1-G67E mutation
has not been reported in 1688 individuals studied in the
general population (Barnetson et al, 2008), consistent with
the mutation being pathogenic. Our observations suggest that
alleles that modify the effect of the G67E mutation (Scott, 2008)
may be present in this family to explain the unusual spectrum.
Alternatively, there may be functions of hMLH1 that are not
assessed simply by determining whether the resulting change
causes a mutator phenotype.
Because of the rarity of tumours in our Lynch syndrome family,
this poses significant clinical management issues regarding
recommendations on screening and treatment. Identification of
more families with this pathogenic mutation could shed light on
the mechanism for carcinogenesis in our kindred.
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